Medical Science Liaison
Alumis
Summary
The Medical Science Liaison (MSL) is a strategic, field-based, scientific expert focused on developing and maintaining collaborative relationships with Dermatology key opinion leaders (KOLs) and other healthcare professionals (HCPs). The MSL will engage with HCPs to support trial enrollment, educate on disease states and clinical trial outcomes, and inform internal strategy by gathering insights and representing the voice of KOLs and HCPs.
Job description
Key Responsibilities Include:
- Develop and maintain collaborative relationships with KOLs in the Dermatology community.
- Utilize systems to strategically map, identify, profile and prioritize thought leaders in line with the medical strategy
- Effectively develop and manage your assigned geography with an entrepreneurial approach
- Support clinical development initiatives including site identification, trial recruitment, timely completion of study milestones, and presentation of data
- Attend and report on assigned medical conferences
- Collaborate with KOLs on medical affairs initiatives including publications, advisory boards, medical education opportunities, training, and speaker development
- Serve as scientific resource to external disease experts and internal stakeholders
- Support the medical community with up-to-date medical information, robust disease expertise, and product information
- Gather and communicate insights from HCPs to inform medical strategy
- Train internal stakeholders on key scientific and medical topics
- Maintain effective and appropriate communication among internal stakeholders while maintaining full compliance with relevant requirements
- Lead and/or contribute to Medical Affair workstreams, projects, or resource development
- Maintain accurate documentation of MSL activities
- Support commercial activities where appropriate
Qualifications
Requirements
- Advanced degree in scientific, clinical, or medical-related discipline (PharmD, PhD, MSN, DNP, PA-C, MPH, etc).
- At least 3 years of experience in MSL role, and must include experience as a Dermatology MSL. Launch, pre-launch, psoriasis, and/or Rheumatology experience is a plus
- Must have well-established networks and active relationships with KOLs in Dermatology and in the territory.
- Candidate must understand compliance considerations and demonstrate ability to work compliantly
- Ability and willingness to travel ~50%. Required travel to medical meetings, team meetings, and other group meetings (will require some weekends).
Skills, Knowledge & Abilities
- Excellent oral and written communication skills
- Excellent interpersonal and engagement skills
- Energetically embraces responsibilities, demonstrates ability to achieve goals
- Demonstrates strong initiative as a flexible and proactive
- Ability to thrive in ambiguous situations
- Solution-oriented approach
- Exhibits excellent time management and ability to prioritize
- Demonstrated ability to work independently
- Experience in a start-up environment is a plus
Requirements
- Advanced degree in scientific, clinical, or medical-related discipline (PharmD, PhD, MSN, DNP, PA-C, MPH, etc)
- At least 3 years of experience in MSL role
- Must include experience as a Dermatology MSL
- Well-established networks and active relationships with KOLs in Dermatology and in the territory
- Understand compliance considerations and demonstrate ability to work compliantly
- Ability and willingness to travel ~50%
- Excellent oral and written communication skills
- Excellent interpersonal and engagement skills
- Demonstrated ability to work independently
- Exhibits excellent time management and ability to prioritize
Benefits
- Health Insurance
- Stock Options
- Annual Bonus Program
- Bus & Ferry Share
- Cell Phone Stipend
- Unlimited PTO
- Onsite Gym
- Snacks and Drinks
Company overview
Alumis is a clinical-stage biopharmaceutical company founded in 2021 and headquartered in South San Francisco, California. The company specializes in developing innovative oral therapies for immune-mediated diseases using a precision medicine approach. Alumis aims to transform patient care by replacing broad immunosuppression with targeted therapies that offer improved efficacy and reduced side effects. The company leverages its proprietary precision data analytics platform to identify optimal therapeutic targets, molecules, indications, and patient populations, thereby optimizing clinical outcomes. Alumis's most advanced product candidate is ESK-001 (envudeucitinib), an oral, highly selective small molecule allosteric inhibitor of tyrosine kinase 2 (TYK2), currently in Phase 3 clinical trials for moderate-to-severe plaque psoriasis and Phase 2 trials for systemic lupus erythematosus. The company also develops A-005, a CNS-penetrant TYK2 inhibitor for neuroinflammatory conditions. Incubated by Foresite Labs, Alumis is led by an experienced team of professionals dedicated to advancing transformative therapies for patients with significant unmet medical needs in autoimmune and inflammatory diseases.